






# Exhibit 2



# Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative Bias Analysis

Katie M. O'Brien, PhD, MSPH<sup>1</sup> ; Nicolas Wentzensen, MD, PhD, MS<sup>2</sup> ; Kemi Ogunsina, MD, PhD, MPH<sup>1</sup>; Clarice R. Weinberg, PhD<sup>3</sup>; Aimee A. D'Aloisio, PhD, MS<sup>4</sup> ; Jessie K. Edwards, PhD, MSPH<sup>5</sup> ; and Dale P. Sandler, PhD<sup>1</sup> 

DOI <https://doi.org/10.1200/JCO.23.02037>

## ABSTRACT

**PURPOSE** Intimate care products may contain substances associated with increased risk of hormone-related cancers. The relationship between genital talc use and ovarian cancer, in particular, has been well studied, but concerns about recall bias and exposure misclassification have precluded conclusions. We examined the association between intimate care products and female hormone-related cancers, accounting for potential biases, using data from a US-based cohort study.

**METHODS** The Sister Study enrolled 50,884 women who had a sister with breast cancer. Data on genital talc use and douching were collected at enrollment (2003–2009) and follow-up (2017–2019). We used Cox proportional hazards models to estimate hazard ratios (HRs) for associations between intimate care product use and breast, ovarian, and uterine cancers. To account for potential exposure misclassification and recall bias, we conducted quantitative bias analyses under various exposure reassignment assumptions.

**RESULTS** Across considered scenarios, 41%–64% of participants douched and 35%–56% used genital talc. In models adjusted for exposure misclassification, genital talc use was positively associated with ovarian cancer (HR range, 1.17–3.34). Frequent douching and douching during young adulthood were positively associated with ovarian cancer, but neither douching nor talc was associated with breast or uterine cancer. Differential reporting of talc use by cases and noncases likely produces positive biases, but correcting for error still resulted in HRs above 1.0. For example, HR, 1.40 (95% CI, 1.04 to 1.89) when 25% of exposed cases and 10% of unexposed noncases had talc status reassigned.

**CONCLUSION** Although results show how differential recall would upwardly bias estimates, corrected results support a positive association between use of intimate care products, including genital talc, and ovarian cancer.

## ACCOMPANYING CONTENT

 Appendix

Accepted March 12, 2024

Published May 15, 2024

J Clin Oncol 00:1-15

© 2024 by American Society of  
Clinical Oncology



View Online  
Article

## INTRODUCTION

Intimate care products may contain endocrine-disrupting chemicals, such as phthalates, parabens, and bisphenols,<sup>1,2</sup> which can alter endogenous hormone levels and potentially affect the risk of developing hormone-related diseases such as breast, ovarian, or uterine cancer. They may also contain other known or suspected carcinogens such as volatile organic compounds<sup>3,4</sup> and asbestos.<sup>5,6</sup>

Douche and powder are two commonly used intimate care products. Douches are liquids inserted into the vagina using a device that produces an upward stream. Initially promoted as contraception,<sup>7</sup> women also douche to improve perceived cleanliness and reduce odor, particularly after sexual intercourse or menstruation.<sup>8</sup> Although some douches contain only water or vinegar, endocrine-disrupting chemicals and

volatile organic compounds have been detected in commercially available products,<sup>2,4</sup> and users have elevated urinary phthalate levels.<sup>9</sup> Douching has been linked to adverse reproductive health outcomes, including pelvic inflammatory disease, bacterial vaginosis, and ectopic pregnancy.<sup>10</sup> It is also considered a risk factor for cervical cancer<sup>10,11</sup> and possibly ovarian cancer.<sup>12,13</sup>

Powder consisting of talc or cornstarch may be applied to the genital area to prevent dampness and chafing, promote a feeling of cleanliness, or reduce odor.<sup>8</sup> Genital powder use became a public health concern because of the natural co-occurrence of talc and asbestos.<sup>6</sup> Although recent surveillance identified asbestos particles in certain talc products,<sup>5</sup> the prevalence of asbestos contamination is unknown, given the lack of routine monitoring. Use of powder in the genital area could plausibly promote carcinogenesis through



## CONTEXT

### Key Objective

Are history of genital talc use and douching associated with breast, ovarian, or uterine cancer after correcting for likely biases?

### Knowledge Generated

Genital talc use was positively associated with ovarian cancer for a range of plausible bias-correction scenarios, with higher rates seen for frequent and long-term users. Douching frequently and during young adulthood were also positively associated with ovarian cancer, but neither douching nor talc was associated with breast or uterine cancer.

### Relevance (G. Fleming)

These findings support the hypothesis that there is a positive association between genital talc use and development of ovarian cancer, but unmeasured confounding could still be present.\*

\*Relevance section written by JCO Associate Editor Gini Fleming, MD.

mechanisms other than direct contact with asbestos, including exposure to other chemicals<sup>1,3</sup> or irritation and inflammation of the reproductive tract.

When considering the potential carcinogenicity of intimate care products, the relationship between genital powder use and ovarian cancer has been especially well studied, although without clear consensus.<sup>14</sup> Initial case-control studies<sup>15-18</sup> indicated a strong positive association that was not replicated in prospective studies,<sup>12,19,20</sup> even when pooled.<sup>21</sup> In studies with retrospective data collection, women with and without ovarian cancer may differentially report exposure, leading to recall bias.<sup>22,23</sup> Although not affected by recall bias, prospective studies tend to have small case numbers and simplified exposure assessments, resulting in low statistical precision and increased likelihood of nondifferential exposure misclassification.

Our main objective was to re-evaluate the associations between intimate care product use and incidence of hormone-related cancers, expanding on previous analyses,<sup>12,24</sup> by incorporating newly diagnosed ovarian and uterine cancers, adding breast cancer as an outcome, and integrating new data on lifetime use of douche and genital talc. Because the newly acquired exposure data were susceptible to differential missingness by cancer status, we used quantitative bias analysis to estimate effects under several missingness assumptions. When examining the association between genital talc use and ovarian cancer, we additionally evaluated the potential impact of recall bias.

## METHODS

### Study Sample

The Sister Study consists of 50,884 women age 35–74 years who had a sister previously diagnosed with breast cancer, but

who did not have breast cancer themselves at enrollment (2003–2009). All resided in the United States and provided written informed consent. The Sister Study is overseen by the institutional review board of the National Institutes of Health.


Participants completed an extensive computer-assisted telephone interview at enrollment, plus a separate personal and intimate care product use questionnaire.<sup>25</sup> Trained examiners took anthropometric measurements. Major health events are reported annually, with extensive follow-up questionnaires completed every 3 years.

We excluded five women who withdrew their consent and 79 with prebaseline breast cancer or unknown status (Fig 1). An additional 994 women were excluded from multivariable analyses because of missing data for key covariates, leaving 49,806. For ovarian cancer analyses, we additionally excluded 225 women with uncertain status or prebaseline ovarian cancer and 8,753 women with previous bilateral oophorectomies. For uterine cancer analyses, we excluded 416 women with uncertain status or prebaseline uterine cancer, as well as 15,202 women with previous hysterectomies. We did not exclude individuals missing data on intimate care product use.

### Exposure Assessment

The initial personal care product questionnaire focused on two specific time periods: age 10–13 years and the 12 months before enrollment. Women were asked how frequently they douched and how frequently they “applied talcum powder to a sanitary napkin, underwear, diaphragm, cervical cap, or directly to your vaginal area.” Participants responded whether they never, sometimes, or frequently used at age 10–13 years, and whether they used never, <1 time/month, 1–3 times/month, 1–5 times/week, or >5 times/week





**FIG 1.** (A) Flowchart and (B) timeline describing characteristics and questionnaire data from Sister Study participants included in the quantitative bias analysis of intimate care product use and incidence of female hormone-related cancers.

in the year before enrollment. We considered frequent use to be at least once per month.

More detailed information about use of douche and genital talc was obtained in the fourth follow-up questionnaire (2017-2019). Participants were asked if they ever used the products, and if yes, their age at first and most recent use, and their frequency of use during each decade. We primarily focused on ever versus never use of each product before enrollment, but we also examined frequency, duration, and timing of use.

Data on intimate care product use were sometimes contradictory or missing. Women who provided contradictory reports about intimate care product use in the year before enrollment<sup>8</sup> were initially categorized on the basis of their enrollment report, but we also considered models where a randomly selected subset was reclassified (details in [Appendix 1](#), online only). We also used quantitative bias analyses to implement different approaches for imputing exposure in women who initially reported never use but did not complete the follow-up questionnaire. These comparisons were crucial for understanding potential biases, as women with incident cancer were overrepresented in this undefined group.

## Outcomes

Incident cases were women who self-reported cancer of the breast, ovary (including fallopian tubes or peritoneum<sup>26</sup>), or uterus after enrollment. These were verified via medical reports, when possible, with some fatal cases confirmed through the National Death Index or death certificates. Data are complete through September 2021 (data release 11.1).

For most breast cancer analyses, we analyzed pre- and postmenopausal person-time separately to account for differential associations with BMI.<sup>27,28</sup> We additionally examined subtype-specific associations on the basis of estrogen receptor status. We separately assessed medically confirmed serous<sup>29</sup> and nonserous ovarian cancer and medically confirmed endometrial cancers (type 1 or 2).<sup>30</sup>

## Covariates

The following covariates were considered potential confounders on the basis of their previously established relationships with intimate care products and hormone-related cancers (all self-reported at enrollment, unless otherwise



specified): race/ethnicity, attained education, examiner-measured BMI, BMI age 30–39 years, age at menarche, duration of hormonal birth control use, parity, menopausal status, hormone therapy use, geographic region of residence, smoking status, and alcohol use. Other covariates included in imputation models because of possible associations with intimate care product use were childhood household income level, adult household income, highest attained education level in the household when the participant was age 13 years, marital status, and weight relative to peers in teen years.

## Statistical Analysis

We first compared covariate distributions across categories of intimate care product use. After excluding women missing key covariates and imputing missing exposure, we used multivariable Cox proportional hazards models with age as the time scale to estimate hazard ratios (HRs) and 95% CIs, adjusting for potential confounders. Follow-up began at enrollment and continued until age at diagnosis, with censoring at the end of follow-up (September 2021), loss to follow-up, or death. For assessments of ovarian and uterine cancers, women were censored at the age of bilateral oophorectomy or hysterectomy, respectively.

In addition to estimating HRs for ever versus never use, we considered the effects of frequent use, long-term use, and use during specific age periods (teens, 20s, 30s, and 12 months before enrollment). Subtype-specific analyses were limited to comparisons of ever versus never use.

We separately estimated HRs for ever versus never use based only on product use as reported at enrollment (prospective) or follow-up (retrospective). Additionally, we considered any product use before the fourth detailed follow-up in relation to cancers occurring after that time (prospective with left truncation). Finally, we conducted sensitivity analyses specific to ovarian cancer, estimating HRs for douching and talc use combined, and for genital talc use according to reproductive tract patency at the time of use.

## Quantitative Bias Analysis

For ever versus never use analyses, we compared four possible scenarios using quantitative bias analysis: (1) no correction; (2) contradictory data correction; (3) contradictory data correction plus categorizing missing or undefined as exposed; and (4) contradictory data correction with multiple imputation of missing or undefined data.

Under no correction, we prioritized reporting at enrollment, categorizing women in the undefined category as nonusers. Women missing both questionnaires were assumed to be missing completely at random. The second scenario added a correction for contradictory data, as described in [Appendix 1](#).

We did this for each of 10 copies of the data, summarizing HRs and 95% CIs using Rubin's rules.<sup>31</sup> Results were consistent across different initiation seeds. For the third scenario, we included the contradictory data correction and categorized all women in the undefined category as users. This contrasted with scenario 2, where the same undefined women were considered never users. Together, scenarios 2 and 3 demonstrate the range of results defined by how women in the undefined category are classified, with the true exposure distribution falling somewhere between the two extremes.

For the fourth scenario, we used multiple imputation with chained equations (MICE; PROC MI, SAS v9.4 [Cary, NC]) to generate covariate-informed probabilistic imputations of the exposure status of participants who were undefined or missing. This scenario should account for covariate-dependent missingness, and we consider it our best estimate of the true association in the absence of recall or other unknown biases. We ran 10 iterations on the data set that already included 10 copies of the data corrected for contradictory responses, then summarized effect estimates across all 100 imputed data sets. We included all the previously described confounders and covariates in the imputation model, as well as each of the cancer outcomes and crude cumulative hazard estimates,<sup>32</sup> which corresponded to the hazard of the earliest of the three cancer events. To ensure that responses regarding ever, frequency, duration, and timing of product use were internally consistent and accounted for coexposure, all talc and douching-related variables were imputed concurrently.

## Recall Bias

We additionally investigated the potential impact of recall bias on the association between genital talc use and ovarian cancer. The initial correction and imputation procedures were identical to scenario 4. Additional details are available in the Supplementary Methods, but briefly, we considered (1) recoding a proportion (range 10%–90%) of ovarian cancer cases classified as talc users to be nonusers; (2) recoding a proportion (range 10%–90%) of ovarian cancer cases classified as nonfrequent and short-term talc users to be nonusers; and (3) re-coding a proportion (range 5%–25%) of noncases classified as nontalc users to be infrequent and short-term talc users.

We also generated a single recall bias-corrected estimate that simultaneously corrected cases and noncases. We assumed 25% of ovarian cancer cases initially categorized as infrequent and short-term users were reassigned to be nonusers and 10% of the women without ovarian cancer initially categorized as never users were re-assigned to be infrequent, short-term users. HRs based on this correction are included in the results as examples of plausible, yet cautious, estimates of the association between genital talc use and ovarian cancer after correcting for case-differential recall.



TABLE 1. Covariate Distributions at Enrollment by History of Genital Talc Use and Douching, Sister Study (2003-2009); n = 50,800

| Covariate                                       | Douching                 |                         |                   | Genital Talc Use         |                         |                   |
|---|--------------------------|-------------------------|-------------------|--------------------------|-------------------------|-------------------|
|   | Never (n = 29,549) (59%) | Ever (n = 20,542) (41%) | Missing (n = 709) | Never (n = 32,541) (65%) | Ever (n = 17,560) (35%) | Missing (n = 697) |
| Age, years, mean (SD)                           | 55.6 (9.3)               | 55.7 (8.5)              | 53.1 (9.0)        | 55.6 (9.2)               | 55.8 (8.6)              | 53.0 (8.9)        |
| Follow-up time, mean (SD)                       | 12.7 (3.4)               | 13.5 (2.5)              | 9.4 (4.8)         | 12.9 (3.2)               | 13.2 (2.9)              | 9.4 (4.9)         |
| Age at menarche, years, mean (SD)               | 12.7 (1.5)               | 12.6 (1.5)              | 12.6 (1.7)        | 12.7 (1.5)               | 12.5 (1.5)              | 12.6 (1.7)        |
| Age at menopause, <sup>a</sup> years, mean (SD) | 50.0 (6.1)               | 49.6 (6.6)              | 48.2 (7.4)        | 49.9 (6.2)               | 49.7 (6.4)              | 48.1 (7.3)        |
| Baseline BMI (kg/m <sup>2</sup> ), mean (SD)    | 27.4 (6.1)               | 28.3 (6.4)              | 30.2 (6.7)        | 27.3 (6.0)               | 28.8 (6.6)              | 30.1 (6.6)        |
| Self-reported BMI in 30s, mean (SD)             | 23.2 (3.8)               | 23.4 (4.2)              | 24.4 (4.7)        | 23.0 (3.8)               | 23.7 (4.3)              | 24.5 (4.6)        |
| Self-reported race/ethnicity, No. (%)           |                          |                         |                   |                          |                         |                   |
| Non-Hispanic White                              | 25,726 (87)              | 16,399 (80)             | 361 (51)          | 27,792 (85)              | 14,337 (82)             | 357 (51)          |
| Non-Hispanic Black                              | 1,500 (5)                | 2,745 (13)              | 214 (30)          | 2,115 (7)                | 2,134 (12)              | 210 (30)          |
| Hispanic/Latina                                 | 1,490 (5)                | 911 (4)                 | 109 (15)          | 1,703 (5)                | 697 (4)                 | 110 (16)          |
| Other   | 824 (3)                  | 482 (2)                 | 24 (3)            | 921 (3)                  | 389 (2)                 | 20 (3)            |
| Attained education, No. (%)                     |                          |                         |                   |                          |                         |                   |
| High school equivalent or less                  | 4,138 (14)               | 3,543 (17)              | 109 (15)          | 4,978 (15)               | 2,708 (15)              | 104 (15)          |
| Some college                                    | 9,179 (31)               | 7,689 (37)              | 294 (42)          | 10,602 (33)              | 6,267 (36)              | 293 (42)          |
| Bachelor's degree                               | 8,541 (29)               | 4,973 (24)              | 176 (25)          | 9,016 (28)               | 4,499 (26)              | 175 (25)          |
| Graduate degree                                 | 7,685 (26)               | 4,332 (21)              | 129 (18)          | 7,937 (24)               | 4,084 (23)              | 125 (18)          |
| Census region, No. (%)                          |                          |                         |                   |                          |                         |                   |
| Northeast                                       | 5,495 (19)               | 2,903 (14)              | 101 (14)          | 5,154 (16)               | 3,242 (18)              | 103 (15)          |
| Midwest   | 8,162 (28)               | 5,298 (26)              | 139 (20)          | 8,940 (27)               | 4,522 (26)              | 137 (20)          |
| South   | 9,306 (31)               | 8,033 (39)              | 348 (49)          | 10,821 (33)              | 6,532 (37)              | 334 (48)          |
| West  | 6,586 (22)               | 4,308 (21)              | 121 (17)          | 7,626 (23)               | 3,264 (19)              | 125 (18)          |
| Ever hormonal birth control use, No. (%)        |                          |                         |                   |                          |                         |                   |
| Never use                                       | 4,919 (17)               | 2,432 (12)              | 117 (17)          | 4,962 (15)               | 2,395 (14)              | 111 (16)          |
| Used, 0-5 years                                 | 11,673 (40)              | 8,178 (40)              | 288 (14)          | 12,841 (40)              | 7,016 (40)              | 282 (41)          |
| Used, >5 years                                  | 12,793 (44)              | 9,828 (48)              | 297 (42)          | 14,550 (45)              | 3,069 (46)              | 299 (43)          |
| Parity, No. (%)                                 |                          |                         |                   |                          |                         |                   |
| No births                                       | 5,295 (18)               | 3,778 (18)              | 121 (17)          | 5,797 (18)               | 3,279 (19)              | 118 (17)          |
| 1 birth   | 3,900 (13)               | 3,331 (16)              | 102 (14)          | 4,713 (15)               | 2,521 (14)              | 99 (14)           |
| 2 births  | 10,822 (37)              | 7,590 (37)              | 246 (35)          | 11,894 (37)              | 6,514 (37)              | 250 (36)          |
| ≥3 births                                       | 9,520 (32)               | 5,822 (28)              | 238 (34)          | 10,119 (31)              | 5,231 (30)              | 230 (33)          |
| Menopausal status, No. (%)                      | 19,463 (66)              | 13,928 (68)             | 400 (56)          | 21,353 (66)              | 12,045 (69)             | 393 (56)          |
| Hysterectomy, No. (%)                           | 8,622 (29)               | 7,115 (35)              | 224 (32)          | 9,745 (30)               | 6,001 (34)              | 215 (31)          |
| Bilateral oophorectomy, No. (%)                 | 5,077 (17)               | 3,963 (19)              | 118 (17)          | 5,613 (17)               | 3,432 (20)              | 113 (16)          |
| Tubal ligation, No. (%)                         | 8,004 (27)               | 6,748 (33)              | 243 (34)          | 9,351 (29)               | 5,399 (31)              | 245 (35)          |

(continued on following page)



**TABLE 1.** Covariate Distributions at Enrollment by History of Genital Talc Use and Douching, Sister Study (2003-2009); n = 50,800 (continued)

| Covariate                                       | Douching                 |                         |                   | Genital Talc Use         |                         |                   |
|---|--------------------------|-------------------------|-------------------|--------------------------|-------------------------|-------------------|
|   | Never (n = 29,549) (59%) | Ever (n = 20,542) (41%) | Missing (n = 709) | Never (n = 32,541) (65%) | Ever (n = 17,560) (35%) | Missing (n = 697) |
| Patent reproductive tract, <sup>b</sup> No. (%) | 15,636 (53)              | 9,128 (44)              | 328 (46)          | 16,581 (51)              | 8,190 (47)              | 321 (46)          |
| Hormone therapy use, No (%)                     |                          |                         |                   |                          |                         |                   |
| Never   | 17,419 (59)              | 11,222 (55)             | 500 (71)          | 18,928 (58)              | 9,722 (56)              | 491 (70)          |
| Unopposed estrogen                              | 5,390 (18)               | 4,530 (22)              | 121 (17)          | 6,169 (19)               | 3,755 (21)              | 117 (17)          |
| Estrogen plus progestin                         | 6,663 (23)               | 4,725 (23)              | 87 (12)           | 7,364 (23)               | 4,021 (23)              | 90 (13)           |
| Smoking, No. (%)                                |                          |                         |                   |                          |                         |                   |
| Never   | 17,340 (59)              | 10,780 (53)             | 391 (55)          | 18,497 (57)              | 9,634 (55)              | 380 (55)          |
| Former  | 9,985 (34)               | 7,897 (38)              | 226 (32)          | 11,395 (35)              | 6,489 (37)              | 224 (32)          |
| Current   | 2,215 (8)                | 1,859 (9)               | 91 (13)           | 2,641 (8)                | 1,431 (8)               | 93 (13)           |
| Alcohol use, No. (%)                            |                          |                         |                   |                          |                         |                   |
| Never or former                                 | 5,557 (19)               | 3,932 (19)              | 169 (24)          | 6,074 (19)               | 3,421 (20)              | 163 (23)          |
| Current, <7 drinks/week                         | 19,898 (67)              | 13,832 (67)             | 466 (66)          | 21,789 (67)              | 11,948 (68)             | 459 (66)          |
| Current, ≥7 drinks/week                         | 4,033 (14)               | 2,743 (13)              | 71 (10)           | 4,610 (14)               | 2,164 (12)              | 73 (11)           |

NOTE. Exclusions: five withdrawals and 79 women diagnosed with breast cancer before completing enrollment. Covariate data were missing as follows (did not use douche [ND], used douche [D], missing douche status [MD], did not use talc [NT], used talc [T], missing talc status [MT]): age at menarche (n = 46 [23 ND, 22 D, one MD; 29 NT, 16 T, one MT]); BMI (n = 17 [12 ND, five D; 10 NT, 7 T]), BMI in 30s (n = 408 [247 ND, 153 D, eight MD; 296 NT, 106 T, six MT]), race/ethnicity (n = 15 [nine ND, five D, one MD; 10 NT, three T, two MT]), attained education (n = 12 [six ND, five ND, one MD; eight NT, two T, two MT]), hormonal birth control use (n = 275 [164 ND, 104 D, seven MD; 188 NT, 80 T, seven MT]), parity (n = 35 [12 ND, 21 D, two MD; 18 NT, 15 T, two MT]), hysterectomy (n = 5 [two ND, three D; three NT, two T]), bilateral oophorectomy (n = 77 [44 ND, 33 D; 47 NT, 30 T]), tubal ligation (n = 16 [12 ND, four D; 13 NT, three T]), patency (n = 1 [one ND; one T]), hormone therapy (n = 143 [77 ND, 65 D, one MD; 80 NT, 62 T, one MT]), smoking (n = 16 [nine ND, six D, one MD; eight NT, six T, two MT]), or alcohol (n = 99 [61 ND, 35 D, three MD; 68 NT, 27 T, four MT]). If baseline and follow-up data are contradictory or the latter is missing, assign status provided at baseline; if missing baseline and not missing follow-up, assign status on the basis of follow-up.

Abbreviation: SD, standard deviation.

<sup>a</sup>Among postmenopausal women.

<sup>b</sup>No hysterectomy and no tubal ligation.



**TABLE 2.** Quantitative Bias Analysis of the Association Between Pre-Enrollment Use of Douche or Genital Talc Use and Female Reproductive System–Related Cancers (n = 49,806)

| Intimate Care Product Exposure and Cancer Status | Scenario 1: No Corrections, Assume Unexposed If Unexposed at Enrollment + Missing at FU, Fill in Missing at Random <sup>a,b</sup> | Scenario 2: Correct Contradictory Data, <sup>c</sup> Assume Unexposed If Unexposed at Enrollment + Missing at FU <sup>a</sup> | Scenario 3: Correct Contradictory Data, <sup>c</sup> Assume Exposed If Unexposed at Enrollment + Missing at FU <sup>a</sup> | Scenario 4: Correct Contradictory Data <sup>c</sup> + Multiple Imputation <sup>a,d</sup> |
|--|---|---|---|--|
| Douching   |   |   |   |  |
| Cohort exposed, %                                | 41  | 43  | 64  | 53   |
| Premeno breast cancer (n = 613)                  |   |   |   |  |
| Never use, HR                                    | 1.00  | 1.00  | 1.00  | 1.00   |
| Ever use, HR (95% CI)                            | 0.76 (0.63 to 0.91)   | 0.73 (0.61 to 0.88)   | 1.18 (0.99 to 1.41)   | 0.87 (0.71 to 1.06)  |
| Postmeno breast cancer (n = 3,927)               |   |   |   |  |
| Never use, HR                                    | 1.00  | 1.00  | 1.00  | 1.00   |
| Ever use, HR (95% CI)                            | 0.85 (0.80 to 0.91)   | 0.84 (0.78 to 0.89)   | 1.16 (1.08 to 1.24)   | 0.96 (0.89 to 1.03)  |
| Ovarian cancer (n = 292)                         |   |   |   |  |
| Never use, HR                                    | 1.00  | 1.00  | 1.00  | 1.00   |
| Ever use, HR (95% CI)                            | 0.69 (0.54 to 0.88)   | 0.67 (0.52 to 0.86)   | 1.86 (1.41 to 2.45)   | 1.03 (0.78 to 1.37)  |
| Uterine cancer (n = 433)                         |   |   |   |  |
| Never use, HR                                    | 1.00  | 1.00  | 1.00  | 1.00   |
| Ever use, HR (95% CI)                            | 0.76 (0.62 to 0.93)   | 0.79 (0.64 to 0.97)   | 1.11 (0.89 to 1.37)   | 0.86 (0.68 to 1.08)  |
| Genital talc use                                 |   |   |   |  |
| Cohort exposed, %                                | 35  | 37  | 56  | 40   |
| Premeno breast cancer (n = 613)                  |   |   |   |  |
| Never use, HR                                    | 1.00  | 1.00  | 1.00  | 1.00   |
| Ever use, HR (95% CI)                            | 0.91 (0.76 to 1.10)   | 0.91 (0.75 to 1.09)   | 1.36 (1.14 to 1.61)   | 0.98 (0.81 to 1.19)  |
| Postmeno breast cancer (n = 3,927)               |   |   |   |  |
| Never use, HR                                    | 1.00  | 1.00  | 1.00  | 1.00   |
| Ever use, HR (95% CI)                            | 0.92 (0.86 to 0.98)   | 0.92 (0.86 to 0.99)   | 1.18 (1.11 to 1.26)   | 0.96 (0.90 to 1.03)  |
| Ovarian cancer (n = 292)                         |   |   |   |  |
| Never use, HR                                    | 1.00  | 1.00  | 1.00  | 1.00   |
| Ever use, HR (95% CI)                            | 1.07 (0.84 to 1.35)   | 1.17 (0.92 to 1.49)   | 3.34 (2.51 to 4.44)   | 1.82 (1.36 to 2.43)  |
| Uterine cancer (n = 433)                         |   |   |   |  |
| (continued on following page)                    |   |   |   |  |



**TABLE 2.** Quantitative Bias Analysis of the Association Between Pre-Enrollment Use of Douche or Genital Talc Use and Female Reproductive System–Related Cancers (n = 49,806) (continued)

| Intimate Care Product Exposure and Cancer Status | Scenario 1: No Corrections, Assume Unexposed If Unexposed at Enrollment + Missing at FU, Fill in Missing at Random <sup>a,b</sup> | Scenario 2: Correct Contradictory Data, <sup>c</sup> Assume Unexposed If Unexposed at Enrollment + Missing at FU <sup>a</sup> | Scenario 3: Correct Contradictory Data, <sup>c</sup> Assume Exposed If Unexposed at Enrollment + Missing at FU <sup>a</sup> | Scenario 4: Correct Contradictory Data <sup>c</sup> + Multiple Imputation <sup>a,d</sup> |
|--|---|---|---|--|
| Never use, HR                                    | 1.00  | 1.00  | 1.00  | 1.00   |
| Ever use, HR (95% CI)                            | 0.98 (0.80 to 1.20)   | 0.98 (0.80 to 1.21)   | 1.28 (1.04 to 1.58)   | 1.01 (0.82 to 1.25)  |

Abbreviations: FU, follow-up; HR, hazard ratio; USD, US dollars.


<sup>a</sup>Adjusted for race/ethnicity (non-Hispanic White, non-Hispanic Black/African American, Hispanic/Latina, other), attained education (high school equivalent or less, some college, college graduate, graduate degree), examiner-measured BMI at enrollment (continuous, kg/m<sup>2</sup>), self-reported BMI age 30-39 years (continuous, kg/m<sup>2</sup>), age at menarche (continuous), hormonal birth control use (never, 0-5 years, >5 years), parity (0, 1, 2, ≥3 births), menopausal status (pre or postmenopausal), hormone therapy use (never, unopposed estrogen only, estrogen plus progestin), smoking status (never, former, current), alcohol use (never or former, current <7 drinks/week, current ≥7 drinks/week), and geographic region (Northeast, Midwest, South, West). Women missing one or more of these potential confounders were excluded (n = 994). An additional 8,978 women excluded from the ovarian cancer analysis because of uncertain ovarian cancer status or prebaseline ovarian cancer (n = 225) or prebaseline bilateral oophorectomy (n = 8,753); 15,618 women excluded from uterine cancer analysis because of uncertain uterine cancer status or prebaseline uterine cancer (n = 416) or prebaseline hysterectomy (n = 15,202).

<sup>b</sup>If baseline and follow-up data are contradictory or the latter is missing, assign status provided at baseline; if missing baseline and not missing follow-up, assign status on the basis of follow-up; if missing both time points, randomly assign exposure status on the basis of overall distribution (assumed missing completely at random).

<sup>c</sup>If report unexposed at baseline but exposed at follow-up and age contradictory, assume 80% truly exposed; if report exposed at baseline but never exposed at follow-up, assume 90% of those truly exposed.

<sup>d</sup>Multiple imputation models included covariates considered confounders for the multivariable analysis in addition to childhood household income level (well off, middle income, low income, poor, missing), adult household income (<\$50,000 USD/year, \$50-99,999 USD/year, ≥\$100,000 USD/year), highest attained education level of the head of the household when the participant was age 13 years (<high school, high school or equivalent, some college, college graduate, missing), marital status (never married, divorced/widowed/separated, married/living as married, missing), weight relative to peers in teen years (lighter, same, heavier, missing), breast cancer (prebaseline/never/incident), ovarian cancer (prebaseline/never/incident), uterine cancer (prebaseline/never/incident), and cumulative hazard values for time to any of the cancer events of interest.





**FIG 2.** Forest plots showing covariate-adjusted hazard ratios (HRs) and 95% CIs for the association between ever genital talc use and incident ovarian cancer across different possible scenarios of recall bias induced by exposure misclassification that differed by ovarian cancer status: (A) scenario 1, (B) scenario 2, and (C) scenario 3.

## RESULTS

In uncorrected data, 41% of women reported ever douching and 35% reported ever using genital talc before enrollment (Table 1). Compared with women who did not douche, women who douched had higher BMI and were more likely to be non-Hispanic Black, live in the South, have a lower attained education, have had gynecologic surgery, have used

unopposed estrogen hormone therapy, and to have smoked. Similarly, genital talc users had higher BMIs than nonusers, and were more likely to be non-Hispanic Black, live in the South, have lower attained education, and have had gynecologic surgery.

The estimated HRs for the uncorrected models where women in the uncertain category (ie, nonusers at enrollment,



**TABLE 3.** Covariate-Adjusted HR and 95% CIs for the Associations Between Douching and Genital Talc Use by Frequency, Duration, and Timing of Use on the Basis of Models With Contradictory Data Corrections and Multiple Imputation

|  |                                   | Premenopausal Breast Cancer (n = 613) |                       | Postmenopausal Breast Cancer (n = 3,927) |                       | Ovarian Cancer (n = 292)<br><i>No Recall Bias Correction</i> |                       | Ovarian Cancer (n = 292)<br><i>Recall Bias Correction<sup>b</sup></i> |                        | Uterine Cancer (n = 433) |                       |
|--|-----------------------------------|---------------------------------------|-----------------------|--|-----------------------|--|-----------------------|---|------------------------|--------------------------|-----------------------|
| Intimate Care Product Exposure         | % Exp in Full Cohort <sup>a</sup> | % Exp                                 | HR (95% CI)           | % Exp                                    | HR (95% CI)           | % Exp  | HR (95% CI)           | % Exp   | HR (95% CI)            | % Exp                    | HR (95% CI)           |
| Douching                               |                                   |                                       |                       |  |                       |  |                       |   |                        |                          |                       |
| Ever v Never use                       | 41/53                             | 44                                    | 0.87 (0.71 to 1.06)   | 53                                       | 0.96 (0.89 to 1.03)   | 56   | 1.03 (0.78 to 1.36)   | —   | —                      | 48                       | 0.86 (0.68 to 1.08)   |
| Never use                              | 59/47                             | 56                                    | 1.00                  | 47                                       | 1.00                  | 44   | 1.00                  | —   | —                      | 52                       | 1.00                  |
| Sometimes use                          | 31/40                             | 38                                    | 0.90 (0.73 to 1.10)   | 38                                       | 0.95 (0.87 to 1.02)   | 35   | 0.88 (0.65 to 1.21)   | —   | —                      | 36                       | 0.86 (0.67 to 1.09)   |
| Frequent use                           | 10/14                             | 6                                     | 0.69 (0.46 to 1.05)   | 15                                       | 0.98 (0.88 to 1.10)   | 21   | 1.50 (1.02 to 2.19)   | —   | —                      | 12                       | 0.87 (0.60 to 1.26)   |
|  |                                   |                                       | <i>P</i> -trend = .08 |  | <i>P</i> -trend = .48 |  | <i>P</i> -trend = .15 |   | —                      |                          | <i>P</i> -trend = .29 |
| Never use                              | 59/47                             | 56                                    | 1.00                  | 47                                       | 1.00                  | 44   | 1.00                  | —   | —                      | 52                       | 1.00                  |
| Short-term use (1 decade only)         | 17/21                             | 18                                    | 0.81 (0.62 to 1.05)   | 21                                       | 0.94 (0.86 to 1.03)   | 16   | 0.72 (0.48 to 1.08)   | —   | —                      | 19                       | 0.80 (0.61 to 1.07)   |
| Long-term use (≥2 decades)             | 24/32                             | 26                                    | 0.93 (0.73 to 1.17)   | 32                                       | 0.96 (0.89 to 1.05)   | 40   | 1.27 (0.94 to 1.72)   | —   | —                      | 29                       | 0.86 (0.65 to 1.13)   |
|  |                                   |                                       | <i>P</i> -trend = .40 |  | <i>P</i> -trend = .40 |  | <i>P</i> -trend = .16 |   | —                      |                          | <i>P</i> -trend = .35 |
| Ever v Never use, teens                | 12/15                             | 16                                    | 0.92 (0.72 to 1.18)   | 12                                       | 0.86 (0.78 to 0.96)   | 12   | 0.76 (0.50 to 1.15)   | —   | —                      | 10                       | 0.73 (0.52 to 1.03)   |
| Ever v Never use to 20s                | 31/42                             | 34                                    | 0.89 (0.72 to 1.09)   | 42                                       | 0.99 (0.92 to 1.06)   | 50   | 1.35 (1.02 to 1.78)   | —   | —                      | 38                       | 0.89 (0.70 to 1.13)   |
| Ever v Never use, 30s                  | 22/30                             | 24                                    | 1.12 (0.90 to 1.41)   | 31                                       | 1.04 (0.96 to 1.13)   | 39   | 1.48 (1.11 to 1.99)   | —   | —                      | 27                       | 0.92 (0.71 to 1.19)   |
| Ever v Never use, year before baseline | 14/14                             | 16                                    | 1.07 (0.85 to 1.35)   | 13                                       | 1.05 (0.95 to 1.16)   | 17   | 1.34 (0.97 to 1.83)   | —   | —                      | 12                       | 0.98 (0.73 to 1.33)   |
| Genital talc                           |                                   |                                       |                       |  |                       |  |                       |   |                        |                          |                       |
| Ever v Never use                       | 35/40                             | 36                                    | 0.98 (0.81 to 1.19)   | 40                                       | 0.96 (0.90 to 1.03)   | 55   | 1.82 (1.36 to 2.43)   | 54  | 1.40 (1.04 to 1.89)    | 42                       | 1.01 (0.82 to 1.25)   |
| Never use                              | 65/60                             | 65                                    | 1.00                  | 60                                       | 1.00                  | 46   | 1.00                  | 45  | 1.00                   | 58                       | 1.00                  |
| Sometimes use                          | 17/19                             | 16                                    | 0.89 (0.69 to 1.14)   | 19                                       | 0.97 (0.88 to 1.06)   | 23   | 1.56 (1.09 to 2.22)   | 24  | 1.18 (0.83 to 1.69)    | 19                       | 0.99 (0.75 to 1.29)   |
| Frequent use                           | 18/20                             | 19                                    | 1.10 (0.87 to 1.39)   | 21                                       | 0.96 (0.88 to 1.05)   | 31   | 1.99 (1.43 to 2.78)   | 31  | 1.81 (1.29 to 2.53)    | 23                       | 1.03 (0.79 to 1.33)   |
|  |                                   |                                       | <i>P</i> -trend = .68 |  | <i>P</i> -trend = .35 |  | <i>P</i> -trend <.001 |   | <i>P</i> -trend = .001 |                          | <i>P</i> -trend = .88 |
| Never use                              | 65/60                             | 65                                    | 1.00                  | 60                                       | 1.00                  | 46   | 1.00                  | 45  | 1.00                   | 58                       | 1.00                  |
| Short-term use (1 decade only)         | 22/23                             | 19                                    | 0.91 (0.72 to 1.13)   | 23                                       | 0.93 (0.86 to 1.01)   | 26   | 1.48 (1.06 to 2.06)   | 28  | 1.17 (0.84 to 1.62)    | 24                       | 0.98 (0.77 to 1.26)   |
| Long-term use (≥2 decades)             | 13/17                             | 16                                    | 1.13 (0.87 to 1.47)   | 17                                       | 1.01 (0.92 to 1.11)   | 27   | 2.20 (1.52 to 3.19)   | 27  | 2.01 (1.39 to 2.91)    | 18                       | 1.08 (0.80 to 1.45)   |
|  |                                   |                                       | <i>P</i> -trend = .67 |  | <i>P</i> -trend = .76 |  | <i>P</i> -trend <.001 |   | <i>P</i> -trend = .001 |                          | <i>P</i> -trend = .76 |
| Ever v Never use, teens                | 15/15                             | 14                                    | 1.06 (0.82 to 1.36)   | 14                                       | 0.95 (0.87 to 1.05)   | 17   | 1.17 (0.84 to 1.63)   | 18  | 0.98 (0.71 to 1.37)    | 14                       | 0.92 (0.69 to 1.23)   |
| Ever v Never use, 20s                  | 15/19                             | 16                                    | 1.02 (0.79 to 1.31)   | 18                                       | 1.00 (0.92 to 1.10)   | 31   | 2.03 (1.49 to 2.77)   | 31  | 1.88 (1.37 to 2.57)    | 18                       | 1.01 (0.77 to 1.33)   |
| Ever v Never use, 30s                  | 11/15                             | 16                                    | 1.30 (1.00 to 1.68)   | 16                                       | 1.11 (1.01 to 1.22)   | 26   | 2.12 (1.53 to 2.96)   | 26  | 2.08 (1.50 to 2.89)    | 15                       | 1.07 (0.80 to 1.44)   |
| (continued on following page)          |                                   |                                       |                       |  |                       |  |                       |   |                        |                          |                       |

(continued on following page)



**TABLE 3.** Covariate-Adjusted HR and 95% CIs for the Associations Between Douching and Genital Talc Use by Frequency, Duration, and Timing of Use on the Basis of Models With Contradictory Data Corrections and Multiple Imputation (continued)

| Intimate Care Product Exposure         | % Exp in Full Cohort <sup>a</sup> | Premenopausal Breast Cancer (n = 613) |                     | Postmenopausal Breast Cancer (n = 3,927) |                     | Ovarian Cancer (n = 292)<br>No Recall Bias Correction |                     | Ovarian Cancer (n = 292)<br>Recall Bias Correction <sup>b</sup> |                     | Uterine Cancer (n = 433) |                     |
|--|-----------------------------------|---------------------------------------|---------------------|--|---------------------|---|---------------------|---|---------------------|--------------------------|---------------------|
|  |                                   | % Exp                                 | HR (95% CI)         | % Exp                                    | HR (95% CI)         | % Exp   | HR (95% CI)         | % Exp   | HR (95% CI)         | % Exp                    | HR (95% CI)         |
| Ever v Never use, year before baseline | 18/18                             | 15                                    | 0.87 (0.69 to 1.10) | 18                                       | 0.92 (0.84 to 1.00) | 17  | 0.91 (0.66 to 1.23) | 18  | 0.83 (0.61 to 1.14) | 21                       | 1.09 (0.86 to 1.39) |

NOTE. Adjusted for race/ethnicity (non-Hispanic White, non-Hispanic Black/African American, Hispanic/Latina, other), attained education (high school equivalent or less, some college, college graduate, graduate degree), examiner-measured BMI at enrollment (continuous, kg/m<sup>2</sup>), self-reported BMI age 30-39 years (continuous, kg/m<sup>2</sup>), age at menarche (continuous), hormonal birth control use (never, 0-5 years, >5 years), parity (0, 1, 2, ≥3 births), menopausal status (pre or postmenopausal), hormone therapy use (never, unopposed estrogen only, estrogen plus progestin), smoking status (never, former, current), alcohol use (never or former, current <7 drinks/week, current ≥7 drinks/week), and geographic region (Northeast, Midwest, South, West). If report unexposed at baseline but exposed at follow-up and age contradictory, assume 80% truly exposed; if report exposed at baseline but never exposed at follow-up, assume 90% are truly exposed. Exposure values imputed if missing both time points or nonuser at baseline and missing follow-up. Multiple imputation models included covariates considered confounders for the multivariable analysis in addition to childhood household income level (well off, middle income, low income, poor, missing), adult household income (<\$50,000 USD/year, \$50-99,999 USD/year, ≥\$100,000 USD/year), highest attained education level of the head of the household when the participant was age 13 years (<high school, high school or equivalent, some college, college graduate, missing), marital status (never married, divorced/widowed/separated, married/living as married, missing), weight relative to peers in teen years (lighter, same, heavier, missing), geographic region of residence (Northeast, Midwest, South, West, missing), breast cancer (prebaseline/never/incident), ovarian cancer (prebaseline/never/incident), uterine cancer (prebaseline/never/incident), and cumulative hazard values for time to any of the cancer events of interest.

Abbreviations: Exp, exposed; HR, hazard ratio; USD, US dollars.

<sup>a</sup>(% before imputation/% after imputation); % of users in comparisons of ever versus never uses, after imputation.

<sup>b</sup>Assume 25% of nonfrequent, short-term users with ovarian cancer misreport their exposure and that 10% of noncases who report no use are actually short-term and infrequent users. Recall bias corrections not made for douching status.



**TABLE 4.** Adjusted HRs and 95% CIs Estimating the Association Between History of Douching, Genital Talc Use, and Female Reproductive System–Related Cancers by Subtype (n = 49,806), on the Basis of Multiple Imputation Models With Contradictory Data Corrections

| Cancer Type                | Cases, No. | Ever Douching, HR (95% CI) | Ever Genital Talc Use, No Recall Bias Correction, HR (95% CI) | Ever Genital Talc Use, Corrected for Recall Bias, <sup>a</sup> HR (95% CI) |
|----------------------------|------------|----------------------------|---|--|
| Breast cancer              | 4,540      | 0.94 (0.88 to 1.00)        | 0.96 (0.90 to 1.03)   | —  |
| Estrogen receptor–positive | 3,272      | 0.93 (0.86 to 1.01)        | 0.96 (0.88 to 1.03)   | —  |
| Estrogen receptor–negative | 574        | 0.99 (0.82 to 1.21)        | 1.00 (0.84 to 1.20)   | —  |
| Ovarian cancer             | 292        | 1.03 (0.78 to 1.36)        | 1.82 (1.36 to 2.43)   | 1.40 (1.04 to 1.89)  |
| Medically confirmed        | 226        | 0.95 (0.69 to 1.31)        | 1.89 (1.37 to 2.62)   | 1.46 (1.06 to 2.02)  |
| Serous                     | 126        | 1.05 (0.69 to 1.59)        | 2.12 (1.38 to 3.26)   | 1.62 (1.06 to 2.48)  |
| Nonserous                  | 100        | 0.83 (0.52 to 1.34)        | 1.64 (1.02 to 2.65)   | 1.29 (0.79 to 2.09)  |
| Uterine cancer             | 433        | 0.86 (0.68 to 1.06)        | 1.01 (0.82 to 1.25)   | —  |
| Medically confirmed        | 338        | 0.91 (0.70 to 1.17)        | 1.05 (0.83 to 1.33)   | —  |
| Endometrial cancer         | 317        | 0.90 (0.68 to 1.17)        | 1.03 (0.81 to 1.32)   | —  |
| Type 1 endometrial cancer  | 257        | 0.91 (0.68 to 1.23)        | 0.99 (0.75 to 1.30)   | —  |
| Type 2 endometrial cancer  | 45         | 0.80 (0.41 to 1.54)        | 1.51 (0.77 to 2.95)   | —  |

NOTE. Adjusted for race/ethnicity (non-Hispanic White, non-Hispanic Black/African American, Hispanic/Latina, other), attained education (high school equivalent or less, some college, college graduate, graduate degree), examiner-measured BMI at enrollment (continuous, kg/m<sup>2</sup>), self-reported BMI age 30–39 years (continuous, kg/m<sup>2</sup>), age at menarche (continuous), hormonal birth control use (never, 0–5 years, >5 years), parity (0, 1, 2, ≥3 births), menopausal status (pre or postmenopausal), hormone therapy use (never, unopposed estrogen only, estrogen plus progestin), smoking status (never, former, current), alcohol use (never or former, current <7 drinks/week, current ≥7 drinks/week), geographic region (Northeast, Midwest, South, West), and an interaction term for BMI and menopausal status at enrollment. Women missing one or more of these potential confounders were excluded (n = 603). An additional 8,952 women excluded from the ovarian cancer analysis because of prebaseline ovarian cancer or prebaseline oophorectomy; 15,473 women excluded from uterine cancer analysis because of prebaseline uterine cancer or prebaseline hysterectomy. Multiple imputation models included covariates considered confounders for the multivariable analysis in addition to childhood household income level (well off, middle income, low income, poor, missing), adult household income (<\$50,000 USD/year, \$50–99,999 USD/year, ≥\$100,000 USD/year), highest attained education level of the head of the household when the participant was age 13 years (<high school, high school or equivalent, some college, college graduate, missing), marital status (never married, divorced/widowed/separated, married/living as married, missing), weight relative to peers in teen years (lighter, same, heavier, missing), geographic region (Northeast, Midwest, South, West, missing), breast cancer (prebaseline/never/incident), ovarian cancer (prebaseline/never/incident), uterine cancer (prebaseline/never/incident), and cumulative hazard values for time to any of the cancer events of interest. If report unexposed at baseline but exposed at follow-up and age contradictory, assume 80% truly exposed; if report exposed at baseline but never exposed at follow-up, assume 90% of those truly exposed.

Abbreviations: HR, hazard ratio; USD, US dollars.

<sup>a</sup>Assume 25% of nonfrequent, short-term users with ovarian cancer misreport their exposure and that 10% of noncases who report no use are actually short-term and infrequent users.

missing follow-up) were categorized as nonusers (Table 2, scenario 1) indicated inverse or weakly positive associations between both types of intimate care products and all cancers of interest. Introducing probabilistic corrections for contradictory responses slightly increased exposure prevalence estimates (scenario 2; 43% douching, 37% talc), but HRs were similar to scenario 1. Under the assumption that all women in the uncertain category were users (scenario 3), prevalence estimates were higher (64% douching, 56% talc), and all estimated HRs were >1.00.

After multiple imputation (Table 2, scenario 4), 53% of participants were categorized as ever douchers and 40% were categorized as ever genital talc users. Douching was not strongly associated with any of the examined outcomes. Ever genital talc use was positively associated with ovarian cancer (HR, 1.82 [95% CI, 1.36 to 2.43]), but showed no evidence of

an association with pre- or post-menopausal breast cancer, or uterine cancer.

If ovarian cancer cases overreported their exposure to genital talc, the HR estimates would be biased upward and away from 1.00 (Fig 2, Appendix Table A1). For example, the HR dropped to 1.41 (95% CI, 1.06 to 1.87) if 25% of cases who only reported being exposed on the postdiagnosis questionnaire were truly unexposed. However, the impact of recall bias was greatly reduced when only short-term, infrequent users were reassigned, with HRs indicating a positive association even when 90% were reclassified (HR, 1.25 [95% CI, 0.95 to 1.65]).

If some noncases reporting never exposure were truly users (albeit infrequent and short-term ones), HR estimates would also be biased up and away from the null. However, the



positive association held when we assumed 15% of noncases (HR, 1.40 [95% CI, 1.04 to 1.88]) had misreported. In a model assuming moderate corrections for both cases (reassign 25% of infrequent/short-term users to be nonusers) and noncases (reassign 10% of nonusers to be infrequent/short-term users), the estimated prevalence of ever talc use changed from 40% (55% in cases) to 45% (54% in cases) and the HR estimate was 1.40 (95% CI, 1.04 to 1.89).

The association between genital talc use and ovarian cancer was higher for frequent (recall bias corrected-HR [HR<sub>rb</sub>], 1.81 [95% CI, 1.29 to 2.53]) and long-term users (HR<sub>rb</sub>, 2.01 [95% CI, 1.39 to 2.91]), compared with never users (both *P* for trend = .001; Table 3). Genital talc use during a woman's 20s and 30s was positively associated with incident ovarian cancer, but HRs were near null for teen use. Frequent douching (HR, 1.50 [95% CI, 1.02 to 2.19]) and douching during a woman's 20s (HR, 1.35 [95% CI, 1.02 to 1.78]) and 30s (HR, 1.48 [95% CI, 1.11 to 1.99]) were also positively associated with ovarian cancer.

Results from analyses limited to medically confirmed cancers were similar, and there were no clear subtype differences (Table 4). Estimates based only on exposure status reported at enrollment were mostly null (Appendix Table A2), except for a possible positive association between douching and ovarian cancer. Cancer cases were underrepresented in analyses relying on follow-up data only, and most HRs were <1.0. The exception was ovarian cancer and genital talc use, where an estimated HR of 2.65 (95% CI, 1.91 to 3.70) could indicate some recall bias. Analyses considering person-time accrued since follow-up questionnaire completion were not subject to recall bias, but had reduced sample size; estimates of the genital talc and ovarian cancer association were consistent with a positive association (HR, 1.84 [95% CI, 0.90 to 3.77]).

Analyses jointly considering patency and genital talc use (Appendix Table A3), relative to never use, showed a potentially stronger association with ovarian cancer among women who used while patent (HR, 1.55 [95% CI, 1.14 to 2.09]). Coadjustment did not notably alter estimates (Appendix Table A4).

## DISCUSSION

Using newly collected data on intimate care product use in a large cohort of US women, we found evidence supporting a positive association between ever genital talc use and incident ovarian cancer. Frequent douching and douching age 20–39 years were also associated with higher rates of ovarian cancer, but neither genital talc use nor douching was consistently associated with breast or uterine cancer. We did not observe clear differences in HRs by subtypes.

Associations between genital talc use and ovarian cancer remained positive, though attenuated, in most quantitative bias analyses addressing missing data biases and potential

differential reporting of genital talc use by ovarian cancer status. In an example scenario correcting for misreporting in both cases and noncases, genital talc use was associated with an approximately 40% higher rate of ovarian cancer, compared with never use, with consistently increasing dose-response patterns for both frequency and duration of use.

These results do not establish causality and do not implicate any specific cancer-inducing agent. Those reporting talc use could be recalling products that contained talc, cornstarch, or a mixture, and women may have used different products at different times. Some talc may have been contaminated with asbestos<sup>5</sup> or other potentially harmful chemicals such as phthalates or parabens.<sup>1,3</sup> Chronic irritation of the ovaries or fallopian tubes from talc or talc-like products could also potentially contribute to carcinogenesis.

Our findings of a positive association between genital talc use and ovarian cancer are consistent with previous studies. Pooled analyses or meta-analyses of case-control studies have produced odds ratios of 1.2–1.4.<sup>33–37</sup> The HR from a pooled analysis of prospective cohort studies<sup>21</sup> also indicated a positive, albeit small association (HR = 1.08), and as previously noted, this effect estimate is likely biased toward the null because of nondifferential misclassification of exposure. This possibility is well illustrated by the Sister Study, where we previously reported 27% ever use of genital talc,<sup>21</sup> but here observe 40% ever use across a wider age range.

Results from the present analysis suggest age 20–39 years may be a window of susceptibility, which is consistent with previous studies that considered ages of use.<sup>38–40</sup> These cover years where hormone levels are high and many women are reproducing. Increased sexual activity during this time period may also correspond to frequent intimate care product use. Additionally, this window occurs before most hysterectomies and tubal ligations are performed, meaning that most women had an intact physical path between application site and the ovaries and fallopian tubes.

Our findings that neither genital talc use nor douching was strongly associated with uterine cancer were consistent with previous literature<sup>24,41,42</sup>; we are unaware of any relevant breast cancer studies. We hypothesized that the endocrine disruptors in douche could affect carcinogenesis for any hormone-related cancer, but only the uterus and ovaries could experience adverse effects caused by direct physical contact. Furthermore, unlike the ovaries and fallopian tube epithelium, uterine epithelium (endometrium) sheds and regenerates frequently via menstruation. This process may flush out the tissue and mitigate talc-induced damage to uterine tissue.

Our exposure assessment included a mix of retrospective and prospective information, integrating some of the strengths and limitations of each data type. Because we only



considered incident cancers, self-reported intimate care product use at enrollment was not influenced by recall bias. However, the Sister Study's overall scope was wide,<sup>25</sup> and the initial intimate care product questions were limited to two specific periods: age 10–13 years and the last year, and did not capture lifetime exposure or use during the most likely exposure period of age 20–39 years.<sup>8</sup>

The follow-up questionnaire included a more comprehensive assessment, but did so after some individuals had been diagnosed with cancer, allowing for the possibility of recall bias.<sup>22,23</sup> Furthermore, those who died of their disease could not have completed the follow-up questionnaire, allowing for bias because of differential missingness. This was particularly problematic for ovarian cancer, which has a low survival rate.<sup>43</sup>

Because the Sister Study is a volunteer cohort of women who have a sister with breast cancer, participants have higher levels of attained education, are more likely to identify as non-Hispanic White, and have a higher average risk of both breast and ovarian cancers, compared with the general US population. Given that patterns of intimate care product use differ by some of these factors,<sup>2,8</sup> our findings may not generalize to all US women or to international populations. Another important limitation was our sample size. Although

the Sister Study is one of the largest studies to collect data on intimate care product use, we lacked statistical power for investigating rare subtypes or differences across subgroups.

Our quantitative bias analyses are a major strength, as they provide a comprehensive illustration of the possible impacts of missing data and recall bias under a variety of scenarios. Although prospectively collected data are preferable for future investigations, our findings demonstrate how retrospective studies can evaluate the possible impact of recall bias. Detailed data on related covariates informed our complex imputations and limited the possibility of residual confounding. However, unmeasured confounding could still be present.

Overall, our findings support the hypothesis that there is a positive association between genital talc use and ovarian cancer incidence, although they do not pinpoint a specific cause or mechanism, and there is still uncertainty as to how much recall bias and missing data could upwardly bias effect estimates. If the underlying biologic mechanisms and causal agents can be confirmed, interventions and policies designed to limit exposure to the harmful components of intimate care products have the potential to reduce ovarian cancer incidence.

## AFFILIATIONS

<sup>1</sup>Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC

<sup>2</sup>Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD

<sup>3</sup>Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC

<sup>4</sup>Social and Scientific Systems, DLH Holdings Corporation, Durham, NC

<sup>5</sup>Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC

## CORRESPONDING AUTHOR

Katie M. O'Brien, PhD, MSPH; Twitter: @Katie\_MOBrien; e-mail: katie.obrien@nih.gov.

## DISCLAIMER

This work was funded by the National Institutes of Health, which had no role in the design, conduct, or interpretation of the study.

## SUPPORT

Supported by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health (Z1AES044005 to D.P.S.).

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO.23.02037>.

## AUTHOR CONTRIBUTIONS

**Conception and design:** Katie M. O'Brien, Nicolas Wentzensen, Dale P. Sandler

**Financial support:** Dale P. Sandler

**Administrative support:** Katie M. O'Brien

**Provision of study materials or patients:** Dale P. Sandler

**Collection and assembly of data:** Katie M. O'Brien, Clarice R. Weinberg, Aimee A. D'Aloisio, Dale P. Sandler

**Data analysis and interpretation:** All authors

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

## REFERENCES

1. Gao CJ, Kannan K: Phthalates, bisphenols, parabens, and triclocarban in feminine hygiene products from the United States and their implications for human exposure. *Environ Int* 136:105465, 2020
2. Johnson PI, Favela K, Jarin J, et al: Chemicals of concern in personal care products used by women of color in three communities of California. *J Expo Sci Environ Epidemiol* 32:864-876, 2022
3. Lin N, Ding N, Meza-Wilson E, et al: Volatile organic compounds in feminine hygiene products sold in the US market: A survey of products and health risks. *Environ Int* 144:105740, 2020
4. Ding N, Batterman S, Park SK: Exposure to volatile organic compounds and use of feminine hygiene products among reproductive-aged women in the United States. *J Womens Health* 29:65-73, 2020
5. Food and Drug Administration: FDA Advises Consumers to Stop Using Certain Cosmetic Products. <https://www.fda.gov/cosmetics/cosmetics-recalls-alerts/fda-advises-consumers-stop-using-certain-cosmetic-products>



6. IARC Working Groups: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Arsenic, Metals, Fibres and Dusts. 100C:219-309, 2012 <https://monographs.iarc.fr/iarc-monographs-on-the-evaluation-of-carcinogenic-risks-to-humans-19/>
7. Ferranti M: "From birth control to that fresh feeling": A historical perspective on feminine hygiene in medicine and media. *Women Health* 49:592-607, 2009
8. O'Brien KM, Ogunsina K, Wentzensen N, et al: Douching and genital talc use: Patterns of use and reliability of self-reported exposure. *Epidemiology* 34:376-384, 2023
9. Branch F, Woodruff TJ, Mitro SD, et al: Vaginal douching and racial/ethnic disparities in phthalates exposures among reproductive-aged women: National Health and Nutrition Examination Survey 2001-2004. *Environ Health* 14:57, 2015
10. Martino JL, Vermund SH: Vaginal douching: Evidence for risks or benefits to women's health. *Epidemiol Rev* 24:109-124, 2002
11. O'Brien KM, Weinberg CR, D'Aloisio AA, et al: The association between douching, genital talc use, and the risk of prevalent and incident cervical cancer. *Sci Rep* 11:14836-14910, 2021
12. Gonzalez N, O'Brien KM, D'Aloisio AA, et al: Douching, talc use, and risk of ovarian cancer. *Epidemiology* 27:797-802, 2016
13. Gabriel IM, Vitonis AF, Welch WR, et al: Douching, talc use, and risk for ovarian cancer and conditions related to genital tract inflammation. *Cancer Epidemiol Biomarkers Prev* 28:1835-1844, 2019
14. Wentzensen N, O'Brien KM: Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence. *Gynecol Oncol* 163:199-208, 2021
15. Cramer DW, Welch WR, Scully RE, et al: Ovarian cancer and talc: A case-control study. *Cancer* 50:372-376, 1982
16. Harlow BL, Cramer DW, Bell DA, et al: Perineal exposure to talc and ovarian cancer risk. *Obstet Gynecol* 80:19-26, 1992
17. Hartge P, Hoover RN, Leshner LP, et al: Talc and ovarian cancer. *JAMA* 250:1844, 1983
18. Whitemore AS, Wu ML, Paffenbarger RS, et al: Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. *Am J Epidemiol* 128:1228-1240, 1988
19. Gertig DM, Hunter DJ, Cramer DW, et al: Prospective study of talc use and ovarian cancer. *J Natl Cancer Inst* 92:249-252, 2000
20. Houghton SC, Reeves KW, Hankinson SE, et al: Perineal powder use and risk of ovarian cancer. *J Natl Cancer Inst* 106:dju208, 2014
21. O'Brien KM, Tworoger SS, Harris HR, et al: Association of powder use in the genital area with risk of ovarian cancer. *JAMA* 323:49-59, 2020
22. Schildkraut JM, Abbott SE, Alberg AJ, et al: Association between body powder use and ovarian cancer: The African American Cancer Epidemiology Study (AACES). *Cancer Epidemiol Biomarkers Prev* 25:1411-1417, 2016
23. Trabert B: Body powder and ovarian cancer risk—What is the role of recall bias? *Cancer Epidemiol Biomarkers Prev* 25:1369-1370, 2016
24. O'Brien KM, D'Aloisio AA, Shi M, et al: Perineal talc use, douching and the risk of uterine cancer. *Epidemiology* 30:845-852, 2019
25. Sandler DP, Hodgson ME, Deming-Halverson SL, et al: The sister study cohort: Baseline methods and participant characteristics. *Environ Health Perspect* 125:127003, 2017
26. American Cancer Society: Ovarian Cancer Stages. 2018. <https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-staging/staging.html>
27. van den Brandt PA, Spiegelman D, Yaun SSSS, et al: Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. *Am J Epidemiol* 152:514-527, 2000
28. Premenopausal Breast Cancer Collaborative Group, Schoemaker MJ, Nichols HB, et al: Association of body mass index and age with subsequent breast cancer risk in premenopausal women. *JAMA Oncol* 4:e181771, 2018
29. Peres LC, Cushing-Haugen KL, Kobel M, et al: Invasive epithelial ovarian cancer survival by histotype and disease stage. *J Natl Cancer Inst* 111:60-68, 2019
30. Clarke MA, Devesa SS, Harvey SV, et al: Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers. *J Clin Oncol* 37:1895-1908, 2019
31. Rubin D: Multiple Imputation for Nonresponse in Surveys. New York, NY, John Wiley & Sons, 1987
32. White IR, Royston P: Imputing missing covariate values for the Cox model: Imputing missing covariate values for the Cox model. *Stat Med* 28:1982-1998, 2009
33. Penninkilampi R, Eslick GD: Perineal talc use and ovarian cancer: A systematic review and meta-analysis. *Epidemiology* 29:41-49, 2018
34. Kadry Taher M, Farhat N, Karyakina NA, et al: Critical review of the association between perineal use of talc powder and risk of ovarian cancer. *Reprod Toxicol* 90:88-101, 2019
35. Terry KL, Karageorgi S, Shvetsov YB, et al: Genital powder use and risk of ovarian cancer: A pooled analysis of 8,525 cases and 9,859 controls. *Cancer Prev Res* 6:811-821, 2013
36. Berge W, Mundt K, Luu H, et al: Genital use of talc and risk of ovarian cancer: A meta-analysis. *Eur J Cancer Prev* 27:248-257, 2018
37. Davis CP, Bandera EV, Bethea TN, et al: Genital powder use and risk of epithelial ovarian cancer in the ovarian cancer in women of African Ancestry Consortium. *Cancer Epidemiol Biomarkers Prev* 30:1660-1668, 2021
38. Mills PK, Riordan DG, Cress RD, et al: Perineal talc exposure and epithelial ovarian cancer risk in the central valley of California. *Int J Cancer* 112:458-464, 2004
39. Rosenblatt KA, Weiss NS, Cushing-Haugen KL, et al: Genital powder exposure and the risk of epithelial ovarian cancer. *Cancer Causes Control* 22:737-742, 2011
40. Cramer DW, Vitonis AF, Terry KL, et al: The association between talc use and ovarian cancer a retrospective case-control study in two us states. *Epidemiology* 27:334-346, 2016
41. O'Brien KM, Tworoger SS, Harris HR, et al: Genital powder use and risk of uterine cancer: A pooled analysis of prospective studies. *Int J Cancer* 148:2692-2701, 2021
42. Neill AS, Nagle CM, Spurdle AB, et al: Use of talcum powder and endometrial cancer risk. *Cancer Causes Control* 23:513-519, 2012
43. National Cancer Institute. Surveillance, Epidemiology, and End Results Program: Cancer Fact Sheets: Ovarian Cancer. 2023. <https://seer.cancer.gov/statfacts/html/ovary.html>



## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

### Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative Bias Analysis

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/jco/authors/author-center](http://ascopubs.org/jco/authors/author-center).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](#)).

No potential conflicts of interest were reported.



## APPENDIX 1. SUPPLEMENTAL METHODS

### Patterns of Inconsistency and Missingness in Exposure Data

When comparing responses from enrollment and the fourth detailed follow-up, 68% and 61% of participants provided nonmissing, noncontradictory responses about their ever use of douche and genital talc, respectively (categories 1, 3, 6, and 7; Appendix Table A5). Prioritizing reporting at enrollment, those who initially reported nonuse but later reported using just before enrollment were preliminarily classified as nonusers (category 2; 3% douching, 3% talc), and those initially reporting using but who later reported never use (category 5; 1% douching, 7% talc) were preliminarily considered users. In later models, we included some corrections for these inconsistencies, designed to simultaneously consider that most women reporting use on a questionnaire probably did use at some time point, and that women probably recalled recent use with higher accuracy than past use. As such, we randomly selected 80% of those initially reporting nonuse and later reporting use to be reassigned as ever users, and allowed 90% of those initially reporting use and later reporting nonuse to remain users (reassigning 10%). These corrections were done independent of other covariates.

A small proportion of women missing data from both questionnaires (category 12; 1% douching, 1% talc) remained missing. Women missing intimate care product data from enrollment but not follow-up (categories 9-11; 1% douching, 1% talc) were categorized on the basis of their follow-up response, and those reporting use at enrollment but missing follow-up (category 8; 6% douching, 8% talc) were considered users.

Because the follow-up questionnaire covered a larger age range than the enrollment questionnaire, we did not want to assume that women who initially reported nonuse but did not complete follow-up had never used, especially since women with cancer were overrepresented in this undefined group (douching: 21% overall, 28% of

premenopausal breast cancer cases, 24% of postmenopausal breast cancers, 39% of ovarian cancer cases, 24% of uterine cancer cases; genital talc: 19% overall, 27% of premenopausal breast cancer cases, 21% of postmenopausal breast cancers, 37% of ovarian cancer cases, 20% of uterine cancer cases). We implemented a quantitative bias analyses approach to help us compare results after implementing varied approaches to correct or impute exposure for women with conflicting, missing, or undefined status.

### Recall Bias Correction

After implementing the MICE-based method described for scenario 4, we implemented recall bias corrections by changing the exposure status of a specified percentage of women with certain characteristics. These were selected at random using the 100-fold augmented data set.

For the first set of recall bias corrections, we recoded a proportion (10%, 25%, 50%, 75%, or 90%) of the ovarian cancer cases to be nonusers if they (1) were nonusers or missing status at enrollment and (2) were categorized as users on the basis of postdiagnostic status or imputation. Because all participants were ovarian cancer-free at enrollment, women who initially reported being users were not considered for reassignment, nor were women who developed ovarian cancer after completing the follow-up questionnaire ( $n = 30$ ).

For the second set of recall bias corrections, we assumed that ovarian cancer cases who reported being frequent or long-term users were likely reporting their exposure accurately, and therefore, left them unaltered and only changed the exposure status of randomly selected ovarian cancer cases (10%, 25%, 50%, 75%, or 90%) who met the above criteria and had been categorized as infrequent and short-term users.

In a third set of recall bias corrections, we examined the impact of assuming a proportion (5%, 10%, 15%, 20%, and 25%) of noncases categorized as nonusers were truly infrequent, short-term users.



**TABLE A1. Correcting for Recall Bias in the Genital Talc and Ovarian Cancer Association**

| Recall Bias Correction Model  | % Ever Used Genital Talc, Full Cohort<br>(n = 40,829) | % Ever Used Genital Talc, Ovarian<br>Cancer Cases (n = 273) | Ever v Never Genital Talc Use, HR<br>(95% CI) |
|---|---|---|---|
| Cases who ever used genital talc reassigned to be nonusers <sup>a</sup>   |   |   |   |
| 0% reassigned   | 39  | 55  | 1.82 (1.36 to 2.43)                           |
| 10% reassigned  | 39  | 52  | 1.64 (1.24 to 2.18)                           |
| 25% reassigned  | 39  | 48  | 1.41 (1.06 to 1.87)                           |
| 50% reassigned  | 39  | 42  | 1.07 (0.81 to 1.40)                           |
| 75% reassigned  | 39  | 36  | 0.82 (0.62 to 1.08)                           |
| 90% reassigned  | 39  | 32  | 0.69 (0.53 to 0.89)                           |
| Cases who used genital talc infrequently and for short-term reassigned to be nonusers <sup>b</sup>  |   |   |   |
| 0% reassigned   | 39  | 55  | 1.82 (1.36 to 2.43)                           |
| 10% reassigned  | 39  | 54  | 1.74 (1.30 to 2.33)                           |
| 25% reassigned  | 39  | 52  | 1.65 (1.25 to 2.17)                           |
| 50% reassigned  | 39  | 50  | 1.48 (1.12 to 1.97)                           |
| 75% reassigned  | 39  | 47  | 1.34 (1.01 to 1.76)                           |
| 90% reassigned  | 39  | 46  | 1.25 (0.95 to 1.65)                           |
| Noncases who never used reassigned to be infrequent, short-term users <sup>c</sup>  |   |   |   |
| 0% reassigned   | 39  | 55  | 1.82 (1.36 to 2.43)                           |
| 5% reassigned   | 42  | 55  | 1.67 (1.25 to 2.23)                           |
| 10% reassigned  | 45  | 56  | 1.53 (1.15 to 2.04)                           |
| 15% reassigned  | 48  | 57  | 1.40 (1.04 to 1.88)                           |
| 20% reassigned  | 51  | 58  | 1.30 (0.97 to 1.74)                           |
| 25% reassigned  | 54  | 59  | 1.19 (0.89 to 1.58)                           |
| Reassign 25% of infrequent,<br>short-term users with ovarian<br>cancer to be nonusers and 10%<br>of noncase, nonusers to be<br>short-term, infrequent users | 45  | 54  | 1.40 (1.04 to 1.89)                           |

**NOTE.** All models also included corrections for contradictory data and multiple imputation for all those missing data on genital talc use as of the fourth detailed follow-up questionnaire, as described previously.

Abbreviation: HR, hazard ratio.

<sup>a</sup>Reassigning x% of participants who met the following criteria to be never users (n ≅ 74): (1) diagnosed with ovarian cancer between enrollment and the fourth detailed follow-up questionnaire; (2) categorized as nonuser of genital talc at enrollment or were missing genital talc data at enrollment; and (3) categorized as ever genital talc user on the basis of the detailed follow-up questionnaire or imputed status.

<sup>b</sup>Reassigning x% of participants who met the following criteria to be never users (n ≅ 7): (1) diagnosed with ovarian cancer between enrollment and the fourth detailed follow-up questionnaire; (2) categorized as nonuser of genital talc at enrollment or were missing talc data at enrollment; (3) categorized as infrequent or short-term genital talc user on the basis of the detailed follow-up questionnaire or imputed status.

<sup>c</sup>Reassigning x% of participants who met the following criteria to be ever users (n ≅ 29,233): (1) not diagnosed with ovarian cancer before the fourth detailed follow-up; (2) categorized as nonuser of genital talc on the basis of follow-up questionnaire or imputed status; (3) categorized as nonuser of genital talc at enrollment or were missing talc data at enrollment.



**TABLE A2.** Uncorrected, Adjusted HRs and 95% CIs for the Association Between Intimate Care Products and Hormone-Related Cancers, on the Basis of Use Reported at Enrollment (age 10-13 years or year before enrollment) or on the Fourth Detailed Follow-Up (any use)

| Defined by Exposure Status Reported on Enrollment Questionnaire (fully prospective, age 10-13 years and in the 12 months before) |           |                               | Defined by Exposure Status Reported on Fourth Detailed Follow-Up Questionnaire (mostly retrospective, any use before enrollment, missing excluded) |           |                               | Defined by Exposure Status Reported on Fourth Detailed Follow-Up (any use before then), and Incident Cases Occurring After That Time (fully prospective) |           |                               |
|--|-----------|-------------------------------|--|-----------|-------------------------------|--|-----------|-------------------------------|
| Intimate Care Product Exposure and Cancer Status   | % Exposed | HR (95% CI), Ever v Never Use |  | % Exposed | HR (95% CI), Ever v Never Use |  | % Exposed | HR (95% CI), Ever v Never Use |
| <b>Douching</b>  |           |                               |  |           |                               |  |           |                               |
| Overall <i>n</i> = 48,618  | 16        |                               | Overall <i>n</i> = 35,725  | 50        |                               | Overall <sup>a</sup> <i>n</i> = 32,891   | 51        |                               |
| Premeno breast cancer<br>596 cases, 48,022 noncases  | 18        | 1.06 (0.85 to 1.31)           | Premeno breast cancer 385 cases, 35,340 noncases   | 38        | 0.84 (0.68 to 1.04)           | Premeno breast cancer 20 cases, 1,619 noncases   | 41        | 1.07 (0.36 to 3.20)           |
| Postmeno breast cancer<br>3,852 cases, 44,766 noncases   | 15        | 1.04 (0.94 to 1.14)           | Postmeno breast cancer 2,747 cases, 32,978 noncases  | 50        | 0.94 (0.87 to 1.02)           | Postmeno breast cancer 579 cases, 32,214 noncases  | 51        | 0.97 (0.82 to 1.15)           |
| Ovarian cancer<br>286 cases, 39,542 noncases   | 19        | 1.30 (0.96 to 1.77)           | Ovarian cancer 141 cases, 29,406 noncases  | 51        | 0.98 (0.71 to 1.34)           | Ovarian cancer 29 cases, 27,189 noncases   | 50        | 1.05 (0.51 to 2.16)           |
| Uterine cancer<br>421 cases, 32,926 noncases   | 13        | 0.94 (0.71 to 1.26)           | Uterine cancer 297 cases, 24,830 noncases  | 46        | 0.87 (0.68 to 1.11)           | Uterine cancer 63 cases, 22,605 noncases   | 48        | 0.94 (0.55 to 1.61)           |
| <b>Genital talc use</b>  |           |                               |  |           |                               |  |           |                               |
| Overall <i>n</i> = 48,648  | 27        |                               | Overall <i>n</i> = 35,760  | 31        |                               | Overall <sup>a</sup> <i>n</i> = 32,922   | 32        |                               |
| Premeno breast cancer<br>597 cases, 48,051 noncases  | 24        | 0.96 (0.79 to 1.17)           | Premeno breast cancer 383 cases, 35,377 noncases   | 29        | 1.09 (0.87 to 1.36)           | Premeno breast cancer 20 cases, 1,618 noncases   | 30        | 1.11 (0.39 to 3.14)           |
| Postmeno breast cancer<br>3,860 cases, 44,788 noncases   | 27        | 0.94 (0.88 to 1.01)           | Postmeno breast cancer 2,753 cases, 33,007 noncases  | 31        | 0.97 (0.89 to 1.05)           | Postmeno breast cancer 577 cases, 32,246 noncases  | 32        | 1.11 (0.94 to 1.33)           |
| Ovarian cancer<br>288 cases, 39,570 noncases   | 28        | 1.02 (0.79 to 1.33)           | Ovarian cancer 140 cases, 29,439 noncases  | 53        | 2.65 (1.91 to 3.70)           | Ovarian cancer 29 cases, 27,224 noncases   | 31        | 1.84 (0.90 to 3.77)           |
| Uterine cancer<br>422 cases, 32,949 noncases   | 31        | 1.08 (0.88 to 1.34)           | Uterine cancer 298 cases, 24,856 noncases  | 34        | 1.08 (0.85 to 1.38)           | Uterine cancer 65 cases, 22,633 noncases   | 30        | 0.55 (0.30 to 1.01)           |

Abbreviation: HR, hazard ratio.

<sup>a</sup>Among women without a breast, ovarian, or uterine cancer diagnosis before they completed the fourth detailed follow-up questionnaire.



**TABLE A3.** Adjusted HRs and 95% CIs for the Association Between Genital Talc Use and Ovarian Cancer Accounting for Patency of the Reproductive Tract at Time of Use

| Patency and Genital Talc Use                                | Cases, No. | HR (95% CI)<br><i>No Recall Bias Correction</i> | HR (95% CI)<br><i>Corrected for Recall Bias<sup>a</sup></i> |
|---|------------|---|---|
| Nongenital talc user  | 133        | 1.00  | 1.00  |
| Genital talc user while had patent reproductive tract       | 148        | 1.83 (1.36 to 2.46)                             | 1.55 (1.14 to 2.09)   |
| Only used genital talc after hysterectomy or tubal ligation | 12         | 1.70 (0.86 to 3.37)                             | 1.38 (0.69 to 2.75)   |

NOTE. Adjusted for race/ethnicity (non-Hispanic White, non-Hispanic Black/African American, Hispanic/Latina, other), attained education (high school equivalent or less, some college, college graduate, graduate degree), examiner-measured BMI at enrollment (continuous, kg/m<sup>2</sup>), self-reported BMI age 30-39 years (continuous, kg/m<sup>2</sup>), age at menarche (continuous), hormonal birth control use (never, 0-5 years, >5 years), parity (0, 1, 2, ≥3 births), menopausal status (pre- or post-menopausal), hormone therapy use (never, unopposed estrogen only, estrogen plus progestin), smoking status (never, former, current), alcohol use (never or former, current <7 drinks/week, current ≥7 drinks/week), geographic region of residence (Northeast, Midwest, South, West), and an interaction term for BMI and menopausal status at enrollment. Patency defined as having a uterus and open fallopian tubes (ie, no hysterectomy and no tubal ligation); For this analysis, only participants who reported using genital talc reference group is nongenital talc users. Multiple imputation models included covariates considered confounders for the multivariable analysis in addition to childhood household income level (well off, middle income, low income, poor, missing), adult household income (<\$50,000 USD/year, \$50-99,999 USD/year, ≥\$100,000 USD/year), highest attained education level of the head of the household when the participant was age 13 years (<high school, high school or equivalent, some college, college graduate, missing), marital status (never married, divorced/widowed/separated, married/living as married, missing), and weight relative to peers in teen years (lighter, same, heavier, missing).

Abbreviations: HR, hazard ratio; USD, US dollars.

<sup>a</sup>Assume 25% of nonfrequent, short-term users with ovarian cancer misreport their exposure and that 10% of noncases who report no use are actually short-term and infrequent users.

**TABLE A4.** Adjusted HRs and 95% CIs for the Association Between Intimate Care Products and Ovarian Cancer, Accounting for Coexposure

| Intimate Care Product Use                                  | % Cases (n = 292) Uncorrected/<br>Corrected | HR (95% CI)<br><i>No Recall Bias Correction</i> | HR (95% CI) <i>Corrected for Recall Bias<sup>a</sup></i> |
|--|---|---|--|
| Nonuser  | 24/24                                       | 1.00  | 1.00   |
| Genital talc user, douche nonuser                          | 20/20                                       | 1.85 (1.23 to 2.77)                             | 1.38 (0.90 to 2.13)                                      |
| Douche user, nongenital talc user                          | 21/22                                       | 0.95 (0.63 to 1.43)                             | 0.97 (0.64 to 1.48)                                      |
| Used both douche and genital talc                          | 35/34                                       | 1.73 (1.19 to 2.52)                             | 1.39 (0.95 to 2.02)                                      |
| Ever v never douching, adjusting for genital talc use      | 56/56                                       | 0.94 (0.71 to 1.25)                             | 0.99 (0.75 to 1.31)                                      |
| Ever v never genital talc use, adjusting for ever douching | 55/54                                       | 1.84 (1.37 to 2.46)                             | 1.40 (1.04 to 1.90)                                      |

NOTE. Correlation between douching and genital talc use: Pearson  $r^2 = 0.18$  (uncorrected), Pearson  $r^2 = 0.16$  (corrected). Adjusted for race/ethnicity (non-Hispanic White, non-Hispanic Black/African American, Hispanic/Latina, other), attained education (high school equivalent or less, some college, college graduate, graduate degree), examiner-measured BMI at enrollment (continuous, kg/m<sup>2</sup>), self-reported BMI age 30-39 years (continuous, kg/m<sup>2</sup>), age at menarche (continuous), hormonal birth control use (never, 0-5 years, >5 years), parity (0, 1, 2, ≥3 births), menopausal status (pre or postmenopausal), hormone therapy use (never, unopposed estrogen only, estrogen plus progestin), smoking status (never, former, current), alcohol use (never or former, current <7 drinks/week, current ≥7 drinks/week), geographic region of residence (Northeast, Midwest, South, West), and an interaction term for BMI and menopausal status at enrollment. Multiple imputation models included covariates considered confounders for the multivariable analysis in addition to childhood household income level (well off, middle income, low income, poor, missing), adult household income (<\$50,000 USD/year, \$50-99,999 USD/year, ≥\$100,000 USD/year), highest attained education level of the head of the household when the participant was age 13 years (<high school, high school or equivalent, some college, college graduate, missing), marital status (never married, divorced/widowed/separated, married/living as married, missing), and weight relative to peers in teen years (lighter, same, heavier, missing).

Abbreviations: HR, hazard ratio; USD, US dollars.

<sup>a</sup>Assume 25% of nonfrequent, short-term users with ovarian cancer misreport their exposure and that 10% of noncases who report no use are actually short-term and infrequent users.



**TABLE A5.** Assigning of Exposure Status as of Enrollment (use in the 12 months before), According to Data Collected at Enrollment (2003-2009) and Detailed Follow-Up 4 (2018-2019)

| Category   | % Participants in Category, Douching |  | % Participants in Category, Genital Talc |  | Quantitative Bias Analysis<br>0 = Unexposed, 1 = Exposed      |   |  |   |
|--|--------------------------------------|--|--|--|---|---|--|---|
|  | Overall                              | Cases (premeno breast/<br>postmeno breast/ovarian/<br>uterine) | Overall                                  | Cases (premeno breast/<br>postmeno breast/ovarian/<br>uterine) | Scenario 1: No Corrections, Fill in<br>Missing <sup>a,b</sup> | Scenario 2: Fill in Missing, <sup>a,b</sup><br>Correct Contradictory Data, <sup>c</sup><br><i>Extreme Unexposed</i> | Scenario 3: Fill in Missing, <sup>b</sup><br>Correct Contradictory Data, <sup>c</sup> If<br>Undefined (unexposed at<br>enrollment, but missing follow-up)<br>Assume Exposed <i>Extreme Exposed</i> | Scenario 4: Correct Contradictory<br>Data, <sup>c</sup> Use Multiple Imputation to<br>Fill in Missing or Undefined <sup>d</sup> |
| Intimate Care Product Use Status   |                                      |  |  |  |   |   |  |   |
| 1. Nonuser at both time points   | 34                                   | 37/32/23/35  | 41                                       | 40/40/20/38  | 0   | 0   | 0  | 0   |
| 2. Nonuser at enrollment, later said<br>used at enrollment<br><i>Eligible for correction</i> | 3                                    | 2/2/2/4  | 3  | 2/3/5/3  | 0   | Randomly select 80% to be<br>exposed  | Randomly select 80% to be<br>exposed   | Randomly select 80% to be<br>exposed  |
| 3. Nonuser at enrollment, later said<br>used with age reports not<br>contradictory           | 25                                   | 12/25/16/21  | 8  | 6/8/9/6  | 1   | 1   | 1  | 1   |
| 4. Nonuser at enrollment, missing<br>at follow-up<br><i>Eligible for imputation</i>          | 21                                   | 28/24/39/24  | 19                                       | 27/21/37/20  | 0   | 0   | 1  | Multiply impute   |
| 5. User at enrollment, never user at<br>follow-up<br><i>Eligible for correction</i>          | 1                                    | 1/1/0/2  | 7  | 3/7/2/7  | 1   | Randomly select 10% to be<br>unexposed  | Randomly select 10% to be<br>unexposed   | Randomly select 10% to be<br>unexposed  |
| 6. User at enrollment and<br>follow-up. Consistent ages                                      | 5                                    | 6/4/4/3  | 8  | 8/7/6/9  | 1   | 1   | 1  | 1   |
| 7. User at enrollment and<br>follow-up but ages somewhat<br>inconsistent                     | 4                                    | 3/4/2/3  | 4  | 2/4/5/5  | 1   | 1   | 1  | 1   |
| 8. User at enrollment, missing<br>follow-up  | 6                                    | 8/5/13/6   | 8  | 9/9/15/10  | 1   | 1   | 1  | 1   |
| 9. Missing enrollment, never user<br>at follow-up  | 0                                    | 0/0/0/0  | 1  | 1/0/0/0  | 0   | 0   | 0  | 0   |
| 10. Missing enrollment, used at<br>age other than enrollment at<br>follow-up                 | 0                                    | 0/0/0/0  | 0  | 0/0/0/0  | 1   | 1   | 1  | 1   |
| 11. Missing enrollment, used at<br>enrollment according to<br>follow-up                      | 0                                    | 0/0/1/1  | 0  | 0/0/0/0  | 1   | 1   | 1  | 1   |
| 12. Missing all  | 1                                    | 2/1/1/2  | 1  | 2/1/1/2  | Assume 41% used douche, 35%<br>used genital talc              | Assume 41% used douche, 35%<br>used genital talc  | Assume 41% used douche, 35%<br>used genital talc   | Multiply impute   |

Abbreviation: USD, US dollars

<sup>a</sup>If enrollment and follow-up data are contradictory or the latter is missing, use status provided at enrollment.

<sup>b</sup>Assumes all those missing douching or genital talc data from both time points are missing completely at random (ie, without respect to disease status or other factors), and randomly impute 41% exposed to douching and 35% exposed to genital talc.

<sup>c</sup>If report unexposed at enrollment but exposed at follow-up and age contradictory, assume 80% truly exposed; if report exposed at enrollment but never exposed at follow-up, assume 90% of those truly exposed.

<sup>d</sup>Multiple imputation models included covariates considered confounders for the multivariable analysis in addition to childhood household income level (well off, middle income, low income, poor, missing), adult household income (<\$50,000 USD/year, \$50-99,999 USD/year, ≥\$100,000 USD/year), highest attained education level of the head of the household when the participant was age 13 years (<high school, high school or equivalent, some college, college graduate, missing), marital status (never married, divorced/widowed/separated, married/living as married, missing), weight relative to peers in teen years (lighter, same, heavier, missing), breast cancer (prebaseline/never/incident), ovarian cancer (prebaseline/never/incident), uterine cancer (prebaseline/never/incident), and cumulative hazard values for time to any of the cancer events of interest.